(Q34042800)

English

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Nicola Gökbuget

2

object named as

Nicola Gökbuget

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Hagop Kantarjian

25

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

5

object named as

Susan O'Brien

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

12

object named as

Robin Foà

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

7

object named as

Hervé Dombret

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Richard A. Larson

10

object named as

Richard A Larson

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Adele K Fielding

8

object named as

Adele K Fielding

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

13

object named as

Mark Litzow

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Alessandro Rambaldi

15

object named as

Alessandro Rambaldi

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1

object named as

Max S Topp

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Gary J Schiller

16

object named as

Gary Schiller

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Stephen J Forman

24

object named as

Stephen J Forman

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Leonard T Heffner

9

object named as

Leonard Heffner

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Anthony S Stein

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Gerhard Zugmaier

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Ralf C Bargou

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Svenja Neumann

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Josep-Maria Ribera

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Monika Brüggemann

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Heinz A Horst

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Chris Holland

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Catherine Jia

20

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Tapan Maniar

21

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Birgit Huber

22

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dirk Nagorsen

23

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

16 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

57-66

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of adults with acute lymphocytic leukemia after second salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of survival by tumor response.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2971170-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)71170-2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34042800&oldid=1987924475"